Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial

BACKGROUND: Amelioration of proteinuria is one of main treatment targets in patients with glomerulonephritis, yet the remission rates are suboptimal. AIM OF THE STUDY: To examine the effect of the sodium–glucose transporter 2 inhibitor (empagliflozin) on proteinuria and kidney function progression,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammad, Hany, Shaaban, Asmaa, Philips, Mariana Victor, Fayed, Ahmed, Abdelaziz, Tarek Samy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Nephrology - Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406661/
https://www.ncbi.nlm.nih.gov/pubmed/36872420
http://dx.doi.org/10.1007/s11255-023-03539-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406661/
https://www.ncbi.nlm.nih.gov/pubmed/36872420
http://dx.doi.org/10.1007/s11255-023-03539-8

Ejemplares similares